Shukra Pharmaceuticals Ltd
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]
- Market Cap ₹ 1,134 Cr.
- Current Price ₹ 259
- High / Low ₹ 259 / 57.5
- Stock P/E 139
- Book Value ₹ 12.4
- Dividend Yield 0.40 %
- ROCE 44.2 %
- ROE 44.7 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 109% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 30.3%
Cons
- Stock is trading at 20.9 times its book value
- Earnings include an other income of Rs.4.13 Cr.
- Working capital days have increased from 90.0 days to 160 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5.11 | 4.44 | 2.60 | 4.82 | 5.14 | 5.34 | 5.66 | 11.84 | 11.18 | 20.48 | 58.83 | 74.57 | 30.20 | |
4.63 | 4.54 | 2.85 | 3.64 | 3.68 | 3.73 | 4.01 | 10.30 | 9.74 | 17.59 | 53.47 | 55.17 | 20.38 | |
Operating Profit | 0.48 | -0.10 | -0.25 | 1.18 | 1.46 | 1.61 | 1.65 | 1.54 | 1.44 | 2.89 | 5.36 | 19.40 | 9.82 |
OPM % | 9.39% | -2.25% | -9.62% | 24.48% | 28.40% | 30.15% | 29.15% | 13.01% | 12.88% | 14.11% | 9.11% | 26.02% | 32.52% |
-2.65 | 0.19 | 1.12 | -0.38 | 0.07 | 0.11 | 0.04 | 0.11 | 0.16 | 0.08 | 1.20 | 2.82 | 4.13 | |
Interest | 0.03 | 0.01 | 0.00 | 0.00 | 0.01 | 0.04 | 0.00 | 0.00 | 0.03 | 0.29 | 0.28 | 0.29 | 0.39 |
Depreciation | 0.73 | 0.78 | 0.60 | 0.45 | 0.47 | 0.74 | 0.96 | 1.48 | 1.47 | 1.66 | 1.84 | 2.05 | 2.59 |
Profit before tax | -2.93 | -0.70 | 0.27 | 0.35 | 1.05 | 0.94 | 0.73 | 0.17 | 0.10 | 1.02 | 4.44 | 19.88 | 10.97 |
Tax % | 0.00% | 8.57% | 51.85% | 65.71% | 52.38% | 44.68% | 36.99% | 82.35% | -90.00% | 26.47% | 0.90% | 6.74% | |
-2.93 | -0.76 | 0.13 | 0.12 | 0.50 | 0.53 | 0.46 | 0.04 | 0.19 | 0.75 | 4.41 | 18.54 | 8.18 | |
EPS in Rs | -0.09 | -0.17 | 0.03 | 0.03 | 0.11 | 0.12 | 0.10 | 0.01 | 0.04 | 0.17 | 1.00 | 4.23 | 1.86 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 15.70% | 14.81% | 17.07% | 0.00% | 0.00% | 10.47% | 4.43% | 5.91% |
Compounded Sales Growth | |
---|---|
10 Years: | 33% |
5 Years: | 67% |
3 Years: | 88% |
TTM: | -73% |
Compounded Profit Growth | |
---|---|
10 Years: | 39% |
5 Years: | 109% |
3 Years: | 410% |
TTM: | -56% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 147% |
3 Years: | 302% |
1 Year: | 194% |
Return on Equity | |
---|---|
10 Years: | 14% |
5 Years: | 22% |
3 Years: | 30% |
Last Year: | 45% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10.17 | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 | 3.91 | 10.95 | 43.79 |
Reserves | -10.60 | 12.26 | 12.39 | 12.51 | 13.01 | 13.44 | 13.81 | 13.85 | 14.03 | 14.78 | 21.38 | 46.69 | 10.50 |
10.12 | 0.31 | 1.20 | 0.04 | 0.04 | 3.58 | 6.06 | 8.05 | 9.77 | 3.38 | 5.08 | 3.16 | 2.73 | |
3.90 | 4.10 | 3.15 | 3.16 | 4.32 | 5.51 | 6.95 | 10.07 | 10.24 | 15.39 | 44.60 | 17.04 | 23.65 | |
Total Liabilities | 13.59 | 18.24 | 18.31 | 17.28 | 18.94 | 24.10 | 28.39 | 33.54 | 35.61 | 35.12 | 74.97 | 77.84 | 80.67 |
10.13 | 9.58 | 9.72 | 9.67 | 10.17 | 14.12 | 15.60 | 17.38 | 17.69 | 17.58 | 20.23 | 19.94 | 19.69 | |
CWIP | 0.05 | 1.66 | 1.68 | 1.68 | 1.64 | 1.66 | 1.66 | 1.66 | 1.66 | 1.66 | 1.66 | 1.66 | 1.66 |
Investments | 0.01 | 0.05 | 0.03 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 |
3.40 | 6.95 | 6.88 | 5.89 | 7.09 | 8.27 | 11.08 | 14.45 | 16.07 | 15.88 | 53.08 | 56.24 | 59.32 | |
Total Assets | 13.59 | 18.24 | 18.31 | 17.28 | 18.94 | 24.10 | 28.39 | 33.54 | 35.61 | 35.12 | 74.97 | 77.84 | 80.67 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-12.12 | -2.90 | -2.03 | 2.72 | -0.29 | 0.84 | 0.26 | 1.24 | 0.54 | 7.99 | 3.17 | -5.20 | |
1.70 | -10.16 | 0.73 | -0.41 | -0.93 | -4.75 | -2.45 | -3.36 | -1.89 | -1.53 | -4.43 | -1.20 | |
5.25 | -18.43 | 1.38 | -1.16 | 0.00 | 3.45 | 2.38 | 1.99 | 1.74 | -6.68 | 4.94 | 12.41 | |
Net Cash Flow | -5.17 | -31.49 | 0.08 | 1.15 | -1.22 | -0.46 | 0.18 | -0.12 | 0.38 | -0.21 | 3.68 | 6.01 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 92.14 | 45.21 | 73.00 | 71.18 | 175.40 | 200.27 | 345.01 | 245.08 | 318.31 | 131.88 | 187.31 | 119.97 |
Inventory Days | 144.82 | 133.79 | 553.65 | 91.77 | 112.31 | 53.23 | 99.55 | 169.12 | 221.37 | 139.30 | 25.45 | 18.96 |
Days Payable | 173.08 | 208.91 | 291.18 | 108.46 | 400.10 | 733.80 | 1,161.36 | 785.97 | 702.33 | 302.93 | 270.77 | 59.25 |
Cash Conversion Cycle | 63.88 | -29.90 | 335.47 | 54.50 | -112.39 | -480.30 | -716.81 | -371.77 | -162.64 | -31.75 | -58.01 | 79.68 |
Working Capital Days | 111.43 | 368.29 | 758.08 | 258.23 | 343.70 | 379.35 | 439.81 | 225.97 | 278.48 | 61.49 | 49.01 | 159.57 |
ROCE % | -1.75% | -5.71% | -0.96% | 6.28% | 7.38% | 5.90% | 3.65% | 0.31% | 1.35% | 5.81% | 18.84% | 44.25% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Feb - Submission of the copy of the newspaper cutting of the extract of Unaudited Financial Results for the quarter and Nine months ended 31st December, 2024.
-
Integrated Filing (Financial)
14 Feb - Integrated financial filing for Q3 2024.
- Submission Of Un-Audited Financial Results Of The Company For The Quarter And Nine Months Ended On 31St December, 2024 14 Feb
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. On 14Th February, 2025 And Submission Of Un-Audited Financial Results Of The Company For The Quarter And Nine Months Ended On 31St December, 2024.
14 Feb - Approved unaudited financial results for Q3 FY 2024-25.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
5 Feb - Newspaper advertisement confirming dispatch of Notice of Postal Ballot
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
SPL is a is WHO-GMP certified integrated manufacturer of formulations like tablet, capsules and small volume parenteral. It has assisted in the development and manufacture
of a variety of drugs and dosage forms and potency variations for many pharmaceutical companies